Taiga Biotechnologies, Inc.
4 clinical trials · Sponsor
◉ Watch Taiga Biotechnologies, Inc.
| Record | Firm | Date |
|---|---|---|
| Safety and Early Efficacy Study of TBX-2400 in Patients With AML or Myelofibrosis (NCT04709458) | Taiga Biotechnologies, Inc. | 2022-09-01 |
| Safety and Early Efficacy Study of TBX-1400 in Patients With Severe Combined Immunodeficiency (NCT02860559) | Taiga Biotechnologies, Inc. | 2021-08-01 |
| Study of TBX-3400 in Subjects With Solid Malignant Tumors Resistant or Refractory to Standard Therapies (NCT04640246) | Taiga Biotechnologies, Inc. | 2021-01-25 |
| Study of TBX-3400 in Patients With Stage III and IV Melanoma Resistant or Refractory to Immune Checkpoint Inhibitors (NCT03385486) | Taiga Biotechnologies, Inc. | 2019-06-02 |
Track Taiga Biotechnologies, Inc. automatically
Every clearance here is in the API, with alerts when new ones post.